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ABSTRACT
CD103+ tumor-infiltrating lymphocytes (TIL) have been linked to specific 
epithelial infiltration and a prolonged survival in high-grade serous epithelial ovarian 
cancer (HGSC). However, whether these cells are induced as part of an ongoing anti-
HGSC immune response or represent non-specifically expanded resident or mucosal 
lymphocytes remains largely unknown. In this study, we first confirmed that CD103+ 
TIL from HGSC were predominantly localized in the cancer epithelium and were 
strongly correlated with an improved prognosis. We further demonstrate that CD103+ 
TIL were almost exclusively CD3+ TCRαβ+ CD8αβ+ CD4- T cells, but heterogeneously 
expressed T cell memory and differentiation markers. Activation of peripheral T cells 
in the presence of HGSC was sufficient to trigger induction of CD103 in over 90% of all 
CD8+ cells in a T cell receptor (TCR)- and TGFβR1-dependent manner. Finally, CD103+ 
TIL isolated from primary HGSC showed signs of recent activation and dominantly 
co-expressed key immunotherapeutic targets PD-1 and CD27. Taken together, our 
data indicate CD103+ TIL in HGSC are formed as the result of an adaptive anti-tumor 
immune response that might be reactivated by (dual) checkpoint inhibition.
INTRODUCTION
High-grade serous epithelial ovarian cancer (HGSC) 
is the most common cause of death from gynecological 
malignancies and is the fifth leading cause of female cancer 
death worldwide [1]. Despite successful initial treatment, 
5-year survival is only 35% as almost all patients with 
advanced disease relapse. This poor prognosis has not 
improved in four decades and novel therapies for HGSC 
are urgently needed [2]. Herein, therapeutic exploitation of 
the immune system may be of value.
The immune system plays an important role in the 
development and control of HGSC, and the presence 
of tumor-infiltrating lymphocytes (TIL) in HGSC is 
associated with prolonged survival [3–5]. Indeed, 
infiltration of T cells, and particularly CD8+ cytotoxic 
T cells (CTL) is associated with an improved prognosis 
for HGSC patients [4–6]. Reactivating CTL is therefore 
an active area of investigation for therapy of HGSC. One 
issue that needs to be considered herein is the distribution 
of the CTL within the tumor. Whereas CTL localized in the 
tumor epithelium are associated with prolonged survival 
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in HGSC patients, stromal CTL are not [6]. Therefore, 
developing immunotherapeutic strategies tailored to the 
specific biology of prognostically favorable intraepithelial 
CTL, whilst not activating potentially inflammatory 
stromal immune cells appears warranted.
The epithelial and stromal CTL populations in 
HGSC can be delineated by expression of the αE integrin 
subunit CD103. In line with this, the total number of 
CD103+ TIL (irrespective of localization) was shown to 
be associated with improved prognosis [7]. By contrast, 
the total number of CD8+ TIL did not associate with an 
improved prognosis [7]. CD103+ TIL therefore represent 
an interesting population for therapeutic targeting. 
However, there are several remaining questions regarding 
CD103+ TIL that need to be addressed before these cells 
can be considered as key players in natural HGSC-directed 
immunological reactions.
CD103 is the prototypical marker for intraepithelial 
lymphocytes (IEL) and tissue-resident memory T cells 
(TRM), and has been linked to persistence of T cells 
involved in immune surveillance after pathogenic 
infection of (barrier) tissue. Indeed, CD103 was reported 
to be expressed on influenza-specific CD8+ T cells in the 
human lung, Epstein-Barr virus (EBV)-specific cells in 
human tonsil, and on vesicular stomatitis virus (VSV)-
specific CD8+ T cells in a mouse model system of VSV 
infection of the brain [8–10]. Since ovarian/tubal tissue 
constitutes a de facto barrier, CD103+ T cells in HGSC 
might simply represent “native” (not tumor-specific) 
IEL or TRM cells expanded due to the inflammatory 
reaction within the tumor. Such cells would have limited 
potential for therapeutic targeting in HGSC and would 
represent a poor biomarker for selection of patients for 
immunotherapy. By contrast, if CD103+ TIL in HGSC 
represent adaptive immune cells that are formed as part 
of an ongoing specific anti-cancer response in HGSC, 
these cells could be harnessed for adoptive cell therapy or 
targeted by e.g. immune checkpoint inhibitors.
To address these questions, we determined the 
ontogeny of CD103+ TIL in HGSC and explored whether 
these cells represent a promising target population for 
HGSC immunotherapy.
RESULTS
CD103 identifies intraepithelial CD8+ TIL with 
prognostic benefit in HGSC
First, we confirmed the recent reports on the 
prognostic benefit of CD103+ TIL in HGSC [7,11] 
in an independent cohort of advanced-stage HGSC 
patients treated with either primary surgery and adjuvant 
chemotherapy (PS; n=84), or neo-adjuvant chemotherapy 
followed by interval surgery (NACT; n=102) [12]. CD3+, 
CD8+ and CD103+ TIL were present in tumors from most 
patients and the distribution of CD3+ and CD8+ TIL in 
tumor epithelium and stroma was similar (Figure 1A). By 
contrast, CD103+ TIL were mainly found in the tumor 
epithelium (Figure 1A). Total CD103+ TIL numbers did 
not differ significantly between patients that received PS 
or NACT therapy (not shown), as reported previously 
for epithelial CD8+ TIL in this cohort [12]. In line with 
the observed epithelial distribution, total CD103+ TIL 
counts per mm2 in these patients correlated strongly to 
intraepithelial CD3+ and CD8+ TIL (r=0.86; p<0.0001 
and r=0.87; p<0.0001, respectively), but weaker to stromal 
CD3+ and CD8+ TIL (r=0.14; p=0.0008 and r=0.59; 
p<0.0001, respectively) (Figure 1B and 1C). Moreover, 
the relative distribution of epithelial CD3+ or CD8+ 
and total CD103+ TIL counts were similar (Figure 1D). 
High total numbers of CD103+, but not total CD8+ TIL, 
were associated with a longer disease-specific survival 
(DSS) in patients treated with PS (p=0.012 and p<0.809, 
respectively) (Figure 1E and 1F). As previously reported 
for epithelial CD8+ TIL [12], total CD103+ TIL did not 
confer prognostic benefit in patients treated with NACT 
(p=0.583) (Figure 1G and Supplementary Figure S1). 
Taken together, our data confirm the restricted distribution 
of CD103+ TIL in the HGSC epithelium and suggest a 
CD3+ CD8+ phenotype for these cells.
CD103+ TIL in HGSC are almost exclusively 
classical CD3+ CD56- TCRαβ+ CD8αβ+ CD4- T 
cells with heterogeneous differentiation status
The marker CD103 has been shown to define IEL 
in mucosal tissues, TRM cells in non-lymphoid tissues, 
TRM cells in lung cancer tissue, but also characterizes T 
cell clones that have been in recent contact with cognate 
epithelial tumor cell lines [13–19]. Therefore, to address 
whether CD103+ TIL in HGSC represent expanded IEL, 
TRM, or classical adaptive T cells that have migrated to 
HGSC tissue as a result of an ongoing immune response, 
we performed in-depth phenotyping on TIL isolated 
from primary HGSC tumors. As tissue dissociation and 
digestion may skew distribution of cell subsets and can 
even cause loss of cell surface antigens, we first studied 
CD103+ TIL infiltration in a side-by-side comparison 
of tissue and digests using 6 matched patient samples. 
Immunohistochemistry for detection of CD3, CD8 and 
CD103 was performed on full slides and complemented 
with flow cytometric analysis of the corresponding 
tumor digest. In all cases, CD103+ CD8+ cells were 
only observed in tumor digests when CD8+ and CD103+ 
cells could be detected in the tumor epithelium by 
immunohistochemistry (data not shown).
Marginal numbers of tumor-infiltrating NK-
cells were observed by phenotyping the immune cell 
subpopulations in the tumor digests (n=10, Figure 2A), 
a finding in line with our previous reports. Furthermore, 
NK-cells expressed CD103 in only 1/10 analyzed digests 
at percentages >1% (Figure 2A). 10/10 patients had a 
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Figure 1: CD103 defines intraepithelial CD8+ TIL with prognostic benefit in HGSC patients. A. Representative images of 
HGSC tissue cores with infiltration of CD3+, CD8+ or CD103+ cells. B. Correlation of total CD103+ cells per tumor core versus epithelial 
CD3+ cells or epithelial CD8+ cells. Line insert represents a hypothetical perfect correlation on the x-and y-axis. C. Correlation of total 
CD103+ cells versus stromal CD3+ cells or stromal CD8+ cells. Line insert represents a hypothetical perfect correlation on the x-and 
y-axis. Spearman's rank correlation coefficient was used to determine correlation between epithelial and stromal CD3+ and CD8+ TIL 
and total CD103+ TIL. D. Box-plots of epithelial CD3+, epithelial CD8+ and total CD103+ cell counts per 1 mm2 HGSC tissue. E. DSS 
(determined by Kaplan-Meier method with Log Rank test) of patients within the PS cohort according to infiltration of total CD103+ cells. 
F. DSS of patients within the PS cohort according to infiltration of total CD8+ cells. G. DSS of patients within the NACT cohort according 
to infiltration of total CD103+ cells.
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detectable CD3+ CD103+ T cell infiltrate, although the 
majority of CD3+ TIL in the digests did not express 
CD103 (Figure 2B) (distribution of subsets per patient 
in Supplementary Figure S2). Importantly, CD103+ and 
CD103- TIL predominantly expressed the αβ chains of the 
T cell receptor (TCR) in conjunction with CD3 (Figure 
2C). Moreover, no CD56 expression on these cells was 
detected (data not shown), excluding both yδ- and NKT-
cells as dominant CD103-expressing T cells in HGSC.
Within the total CD3+ TCRαβ+ T cell population, 
both CD8+ and CD4+ cells were detected at roughly a 1:1 
ratio (Figure 2D). By contrast, CD3+ TCRαβ+ CD103+ T 
cells were almost exclusively CD8+, with only marginal 
numbers of CD4+ cells detected (Figure 2D, p<0.0001). 
Notably, all cells expressing the CD8α chain also 
expressed the CD8β chain, and no cells were found to co-
express CD4. As IEL are characterized by co-expression of 
CD4 and CD8α (but not CD8β), this suggests that CD103+ 
T cells in HGSC are not of an IEL origin. Interestingly, a 
subset of ~20-30% of all CD3+ TCRαβ+ CD8αβ+ cells 
expressed both CD8α and β chains at a lower level of 
roughly 50% of the mean fluorescent intensity, irrespective 
of CD103 expression (Figure 2E). The lower expression 
of CD8β has previously been reported in association 
with effector differentiation of T cells and suggests 
both CD103+ and CD103- T cells undergo similar 
differentiation in the HGSC microenvironment.
Finally, to address the resident memory status of 
the CD103+ TIL population, we analyzed expression 
of memory markers CD45RO, CCR7, CD27 and CD28 
in conjunction with CD3, CD8 and CD103 expression 
in two additional HGSC digests (flow cytometric plots 
and gating strategy in Supplementary Figure S3). In line 
with our recent report on the differential expression of 
CD27 and CCR7/CD45RO in HGSC, TIL in these HGSC 
digests could be readily typed to various populations such 
Figure 2: CD103+ TIL are almost exclusively classical CD3+ CD56- TCRαβ+ CD8αβ+ CD4- T cells with heterogeneous 
differentiation status. HGSC tumor tissue was subjected to enzymatic digestion and analyzed by flow cytometry. A. Dot plot representing 
the percentage of CD56+ CD103- cells and CD56+ CD103+ cells within the total lymphocyte population isolated from HGSC tumor 
digests (N=10). B. Percentage of CD103- cells and CD103+ cells within the CD3+ cell population. C. Percentage of TCRαβ- and TCRαβ+ 
cells within the total CD3+ population or within the CD3+ CD103+ subpopulation. D. Percentage of CD4+ and CD8+ cells within the total 
CD3+ TCRαβ+ population or within the CD3+ TCRαβ+ CD103+ subpopulation. E. Percentage of CD8αβlow and CD8αβhigh cells within 
the total CD3+ TCRαβ+ CD8αβ+ population or within the CD3+ TCRαβ+ CD8αβ+ CD103+ subpopulation. F. Bar graph of phenotypical 
subtype for CD103+ cells and CD103- cells derived from HGSC tumor digest #202. G. Bar graph of phenotypical subtype for CD103+ 
cells and CD103- cells derived from HGSC tumor digest #207. TCM: central memory T cell. TEM: effector memory T cell. TTD: terminally 
differentiated T cell. Differences were assessed by Mann-Whitney U or one-way ANOVA tests.
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as central memory (TCM), effector memory 1-4 (TEM1-4) 
and terminally differentiated (TTD) subtypes (Figure 2F 
and 2G). Nevertheless, TCM, TEM and TTD subtypes were 
observed in both CD103+ and CD103- CD8+ T cell 
populations and variation between CD103+ and CD103- 
cells was similar to variation between the two HGSC 
patient samples (Figure 2F and 2G). These data support a 
heterogeneous differentiation status of CD103+ TIL, not 
directly in line with a TRM phenotype.
Our data therefore suggest CD103+ TIL in HGSC 
represent T cells of a classical CD3+ CD56- TCRαβ+ 
CD8αβ+ CD4- phenotype of varying differentiation. This 
phenotype is consistent with cells that have infiltrated as a 
result of an adaptive immune response.
Activation in the presence of HGSC cells induces 
CD103 on peripheral blood CD8+ T cells 
through combined TCR- and TGFβR1-signaling
The non-IEL, non-TRM phenotype of CD103+ TIL in 
HGSC prompted us to speculate that induction of CD103 
occurs as a natural consequence of peripheral blood T 
cell activation after infiltrating the HGSC epithelium. To 
assess this, we co-cultured peripheral blood mononuclear 
cells (PBMC) with HGSC cell lines and determined 
expression of CD103 in the presence or absence of a CD3 
agonistic antibody (n≥3 donors). As exemplified in Figure 
3A, activation of T cells in the presence of HGSC cell 
line PEA-1 induced expression of CD103 on a subset of 
~25% of PBMC. Similar percentages were observed in the 
presence of a panel of HGSC cell lines, but not when T 
cells were activated alone (Figure 3A and 3B; n≥3 donors). 
In line with the ex vivo phenotyping data, co-culture of 
PBMC with OVCAR-3 cells predominantly induced 
CD103 on T cells of a CD8αβ+ phenotype, with much 
lower percentages observed in CD4+ cells (Figure 3C and 
3E). A small subset of CD56- CD8- CD4- lymphocytes 
also upregulated CD103 in response to stimulation with 
anti-CD3 agonistic antibody in this setting (Figure 3D 
and 3F), although the exact identity of these cells remains 
unclear. Of note, T cell proliferation did not correlate 
directly with the induction of CD103 on T cells (Compare 
Supplementary Figure S4A with Figure 3B), and both 
CD103+ and CD103- CD8+ cells underwent proliferation 
in co-culture with HGSC (exemplified for PEA-1 in 
Supplementary Figure S4B).
Based on the known role of TGF-β in the induction 
of CD103 in mouse models and T cell clones [20, 21], 
we next assessed whether concurrent T cell activation 
and TGF-β receptor signaling was required for CD103 
induction in PBMC:HGSC co-cultures (n≥3 donors). 
Induction of CD103 on PBMC was fully abrogated 
in the presence of TGF-β receptor I (TGFβR1) kinase 
inhibitor SB-431542 (Figure 3G) without affecting T cell 
proliferation (Figure 3H). To exclude an effect of selective 
depletion of CD8+ cells by TGFβR1 inhibition, we also 
analyzed the relative distribution of CD8 versus CD4 cells 
after treatment with either TGFβR1 kinase inhibitor alone, 
anti-CD3 agonistic antibody or the combination of both. 
While T cell activation with anti-CD3 agonist skewed the 
cell population towards a CD8+ phenotype, this change 
was not affected by treatment with TGFβR1 inhibitor 
(Supplementary Figure S4C). Finally, to confirm a causal 
role for TGF-β in the induction of CD103 on peripheral 
CD8+ T cells, we activated T cells in the presence or 
absence of recombinant TGF-β (rTGF-β1). Treatment with 
rTGF-β1 did not affect T cell proliferation as assessed by 
CFSE dilution, but induced a significant upregulation of 
CD103 (Supplementary Figure S4D and S4E). These data 
suggested that cancer antigen-specific circulating CD8+ T 
cells can upregulate CD103 after activation in the presence 
of HGSC cancer cells through a combination of TCR- and 
TGFβR1-signaling.
To demonstrate that CD103 is indeed induced 
on cancer antigen-specific T cells during an ongoing 
antitumor immune response against HGSC, we employed a 
cytomegalovirus (CMV) model system. OVCAR-3 HGSC 
cells were transfected with the pp65 protein of CMV. 
Activation and antitumor activity were then assessed using 
PBMC from a healthy CMV-seropositive donor. After 5 
days of co-incubation, CD103 was induced on ~20% of all 
CD8+ cells and these CD103+ cells (but not CD103- cells) 
co-expressed classical markers of T cell activation such as 
CD137 and HLA-DR (Figure 4A-4C). As observed earlier 
(Figure 3), PBMC co-cultured with wildtype OVCAR-3 
cells in the absence of an activating signal did not induce 
CD103, nor did these cells upregulate CD137 and HLA-
DR (Figure 4A-4C). Induction of CD103 and upregulation 
of CD137 and HLA-DR was abrogated by treatment with 
MHC class I blocking antibody W6/32, demonstrating 
antigen specificity (Figure 4A-4C). Of note, CD4+ T 
cells did not upregulate CD103 (Figure 4A), nor CD137, 
HLA-DR, and OX40 (not shown). Concomitant to the 
induction of CD103, T cells in these co-cultures induced 
specific apoptosis in pp65+, but not wildtype, OVCAR-3 
cells (Figure 4D). Finally, isolation of CD103+ versus 
CD103- negative cells after 5 day co-culture revealed 
that the specific recognition and apoptotic capacity were 
restricted to the CD103+ cell population (Figure 4E). 
Taken together, these data indicate that CD103 is induced 
on polyclonal and polyfunctional cancer antigen-specific 
CD8+ T cells in response to specific recognition of HGSC 
cells in the presence of TGF-β produced by the epithelium.
CD103+ TIL in situ are characterized by ongoing 
TCR- and TGFβR1-signaling
To confirm this proposed mode of action for the 
ontogeny of CD103+ TIL in situ, we first assessed whether 
CD103+ TIL in HGSC tumor tissue demonstrated signs of 
active TGF-β signaling [22]. Hereto, paraffin-embedded 
tissue of HGSC was probed by fluorescent microscopy 
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Figure 3: Activation in the presence of HGSC cell lines induces CD103 on peripheral blood CD8+ T cells through 
combined TCR and TGFβR1-signaling. PBMCs were isolated and cultured in the presence of HGSC cell lines. A. Histograms 
representing CD103 expression on PBMCs after incubation of PBMCs with anti-CD3 agonistic antibody (CD3 agonist) in the presence 
or absence of HGSC cell line PEA-1. B. Bar graph representing the percentage of CD103+ cells after incubation of PBMCs with HGSC 
cell lines (PEA-1, PEA-2, PEO-14, PEO-23, OVCAR-3) in the presence or absence of CD3 agonist. C. Representative flow cytometry 
images of CD103 expression on the CD8+ T cell and CD4+ T cell populations after incubation with OVCAR-3 and CD3 agonist. 
D. Representative flow cytometry image of CD103 expression on the CD8-CD4- T cell population after incubation with OVCAR-3 and 
CD3 agonist. E. Representative flow cytometry images of CD103 expression on the CD8+ T cell and CD4+ T cell populations after 
incubation with OVCAR-3 without CD3 agonist (control). F. Representative flow cytometry image of CD103 expression on the CD8-
CD4- T cell population after incubation with OVCAR-3 without CD3 agonist (control). G. Bar graph representing the percentage CD103 
expressing cells after incubation of PBMCs with HGSC cell lines (PEA-1, PEO-14, OVCAR-3) and TGFβR1 inhibitor and/or CD3 agonist 
as indicated. H. Representative images of CFSE dilution showing T cell proliferation after incubation of PBMCs with OVCAR-3 and 
TGFβR1 inhibitor and/or CD3 agonist as indicated, showing CD103 expression on the y axis. Differences were assessed by Mann-Whitney 
U or one-way ANOVA tests.
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for simultaneous expression of CD8, CD103 and nuclear 
pSMAD2/3, a hallmark of TGF-β signaling. HGSC 
tumor epithelial islets were characterized by a pronounced 
nuclear expression of pSMAD2/3 (Figure 5A), a finding 
confirmed in a subsequent set of 37 HGSC patients by 
immunohistochemistry (Supplementary Figure S5A). 
Moreover, CD8+ CD103+ TIL, but not CD8+ CD103- TIL 
localized almost exclusively to these pSMAD2/3+ tumor islets 
Figure 4: Activation in the presence of HGSC cell lines induces CD103 on CMV pp65-reactive CD8+ tumor-lytic T 
cells. PBMCs from a CMV seropositive donor were isolated and cultured in the presence of OVCAR-3 wildtype (OVCAR-3 wt) cells 
or OVCAR-3 cells transduced with CMV pp65 (OVCAR-3 pp65) for 5 days (n=3). A. Representative flow cytometry images of CD103 
expression on the CD8+ T cell and CD4+ T cell populations after co-incubation for 5 days with OVCAR-3 wt or OVCAR-3 pp65 alone 
or in the presence of MHC class I blocking antibody W6/32. B. Histograms representing CD137 or C. HLA-DR expression on CD103+ 
and CD103- CD8+ PBMCs after co-incubation for 5 days with OVCAR-3 wt or OVCAR-3 pp65 alone or in the presence of MHC class I 
blocking antibody W6/32. D. Percentage of apoptotic OVCAR-3 wt or OVCAR-3 pp65 tumor cells after co-culture with PBMCs for 5 days. 
E. Histograms representing CD103 expression on sorted CD103- and CD103+ cells after 5 day co-incubation with OVCAR-3 pp65 cells 
(left), and percentage of apoptotic OVCAR-3 wt or OVCAR-3 pp65 tumor cells after co-culture with sorted CD103- or CD103+ cells for 
48 hours (right). Differences were assessed by Mann-Whitney U or one-way ANOVA tests.
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(Figure 5A). Subsequent confocal analysis revealed that CD8+ 
CD103+ TIL were characterized by nuclear pSMAD2/3 
expression, whereas CD8+ CD103- TIL were largely negative 
for pSMAD2/3 expression (Figure 5B, 5C and Supplementary 
Figure S5B-S5C). Of note, while a significant number of 
stromal cells in HGSC tumors expressed pSMAD2/3 in the 
nucleus, these cells were all negative for CD8 (Supplementary 
Figure S5C), suggesting a non CTL-origin.
Figure 5: CD103+ TIL in situ are characterized by ongoing TCR and TGFβR1-signaling. A-C. FFPEtissue slides from 
HGSC patients were used for immunofluorescent staining. A. Representative single and multichannel images of tissue from a patient with 
HGSC stained for DNA (orange), pSMAD2/3 (green), anti-CD8 (yellow) and anti-CD103 (blue). B. Representative single and multichannel 
images ofCD8+ CD103+ pSMAD2/3+ intraepithelial and CD8+ CD103- pSMAD2/3- stromal cells. CD8+CD103+ cells are depicted with 
an arrow. C. Representative image by confocal microscopy of a cross section of a CD8+ CD103+ T cell. CD8 and CD103 are expressed 
on the cell membrane whereas DAPI and pSmad2/3 are expressed within the nucleus. D. HGSC tumor tissue was subjected to enzymatic 
digestion and analyzed by flow cytometry. The percentage of CD137+ cells within the CD8+ CD103+ and CD8+ CD103- T cell populations 
is indicated. Differences were assessed by Mann-Whitney U tests.
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To assess TCR signaling, we determined the 
expression of the marker for recent T cell activation 
CD137 [23] in several HGSC digests (n=6). In almost 
all cases, CD137 was expressed on a significantly higher 
fraction of CD103+ cells than on CD103- cells (Figure 5D, 
p=0.008). Taken together, our data suggest that CD103 
expression on CD8+ TIL in situ is likely the result of 
concurrent TCR- and TGFβR1-signaling.
CD103+ HGSC TIL dominantly express 
checkpoint molecules PD-1 and CD27
Our data suggested CD8+ CD103+ T cells are an 
adaptive immune population infiltrating the epithelial 
bed of HGSC. Therefore, checkpoint molecules 
expressed on CD103+ cells may represent key targets 
for immunotherapy in HGSC. To assess this, we 
screened a series of HGSC digests (n≥3) for expression 
of clinically relevant antibody targets on CD8+ CD103+ 
and CD103- T cells. CD8+ CD103+TIL displayed a 
statistically significant higher percentage of PD-1+ cells 
when compared to their CD103- counterparts (Figure 
6A, p=0.04). In addition, expression of the pro-apoptotic 
molecule Fas was higher in CD103+ cells (Figure 6A, 
p>0.05), in line with a recent report on a FasL-mediated 
endothelial barrier in epithelial islets in HGSC [24]. 
Immune checkpoint molecules TIM-3, LAG-3 and CTLA-
4 could not be detected in HGSC digests (not shown). 
Expression of clinically relevant immune checkpoints 
from the tumor necrosis factor (TNF) family was largely 
restricted to expression of CD27, although no differences 
were observed between CD103+ and CD103- cells 
(Figure 6A). Finally, as described above, CD103+, and to 
a significantly lesser extent, CD103- cells expressed the 
marker of recent T cell activation CD137 (Figure 6A). To 
confirm the dominant co-expression of CD27 on CD103+ 
CD8+ TIL, we analyzed serial sections of our patient 
cohort (n=186; see also Figure 1). As anticipated based 
on our flow cytometric analysis of CD27 expression, 
both epithelial CD27+ and stromal CD27+ cells could be 
observed (Supplementary Figure S6A). Epithelial CD27+ 
cells co-localized with CD103+ cells and epithelial CD8+ 
cells in the adjacent sections (Supplementary Figure 
S6A). Analysis of the number of cells revealed a striking 
correlation between total CD103+ cells and epithelial 
CD8+ and epithelial CD27+ cells (Supplementary Figure 
S6B). Taken together, these data identify PD-1, CD137 
and CD27 as key targets for therapeutic reactivation of 
intraepithelial T cells in HGSC.
CD103+ HGSC TIL poorly expand during 
standard IL-2 culture for adoptive T cell therapy
We speculated that the prolonged contact of CD103+ 
CD8+ TIL with the cancer islets might render these cells 
less fit to expand on IL-2. Therefore, we assessed whether 
CD103+ TIL could be expanded from HGSC digests using 
a standard culture protocol of 6000 U/mL of IL-2 (n=6). 
After 7 days, CD103+ T cells were readily detected in 
IL-2 cultures and co-expressed CD8, but not CD4 (Figure 
6B). Similar to the HGSC digests, CD8+ CD103+ cells 
expressed CD137 and were negative for OX40, whereas 
CD4+ TIL expressed high levels of OX40 at the cell 
surface (Figure 6B). Notably, prolonged IL-2 culture 
(3 weeks) resulted in a significant loss of CD103+ T cells 
from the TIL product (Figure 6C). Indeed, analysis of 4 
distinct TIL cultures revealed a predominant expansion 
of CD4+ and/or CD8+ CD103- cells over CD8+ CD103+ 
cells (Figure 6D). In line with this, CD8+ CD103+ cells 
underwent less rounds of cellular proliferation during 
IL-2 culture compared to CD8+ CD103- and CD4+ 
cells (Figure 6E). Taken together, these data highlight 
a defective expansion of intraepithelial CD8+ TIL in a 
clinically relevant IL-2 expansion culture.
DISCUSSION
In the current study we demonstrate that CD103+ 
T cells in HGSC are classical TCRαβ+ CD8αβ+ T cells. 
These cells are generated as a consequence of contact 
between tumor-infiltrating CD8+ T cells and the epithelial 
micro-environment. In addition, we confirm the previously 
published prognostic benefit of total CD103+ TIL in 
HGSC, but demonstrate that this benefit is restricted to 
patients receiving primary cytoreductive surgery (PS). Our 
data further suggest that CD103+ TIL could be effectively 
targeted by dual PD-1/CD27 checkpoint modulation. 
Finally, we propose that novel expansion protocols for TIL 
from HGSC are likely required to maintain the CD103+ 
population for adoptive transfer.
Our data support the notion that CD103 defines 
CD8+ cells that are localized in the epithelial compartment 
of epithelium-derived tumors. Indeed, previous work in 
HGSC, non-small cell lung cancer (NSCLC), urothelial 
cell carcinoma of the bladder and endometrial cancer all 
suggest CD103+ TIL infiltration is restricted to epithelial 
cancer islets [7, 16, 25–27]. However, our study also 
highlights key differences in the observed phenotypes 
for CD103+ TIL between malignancies. In NSCLC, 
CD103+ TIL were found to be of a homogeneous 
CD69+ CD62L− CD28− CD27+ CD45RA+ CD45RO+ 
CCR7− subtype [16]. By contrast, we recently found that 
CD103+ TIL in endometrial cancer were of a CD45RA-
CD45RO+CCR7+/- phenotype [27]. Here, we demonstrate 
that in HGSC CD103+ TIL were homogeneously 
CD3+ CD56- TCRαβ+ CD8αβ+ CD4- CD45RO+, 
but heterogeneously expressed differentiation markers 
CCR7, CD27, and CD28. Furthermore, we demonstrate 
that almost all peripheral blood CD8+ T cells rapidly 
upregulate CD103 after activation in the presence of 
HGSC cancer cells in a TGF-β-dependent manner. These 
data suggest that CD103+ TIL are formed as a consequence 
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Figure 6: CD103+ TIL dominantly express checkpoint molecules PD-1 and CD27. HGSC tumor tissue was subjected to 
enzymatic digestion and analyzed by flow cytometry. A. Bar graph representing the percentage of cells positive for the indicated checkpoint 
molecules stratified by T cell population. B. Representative flow cytometry image of CD103 (x-axis) versus CD28, CD137 and OX40 
(y-axis) (co-)expression within the CD8+ T cell (upper row) and the CD8- T cell population (lower row). C. Percentage of CD103 + cells 
within the CD3+ cell population after prolonged IL-2 culture (3 weeks). D. Pie charts representing percentage of indicated cell populations 
before and after prolonged IL-2 culture (3 weeks). TIL were derived from tumor digests (N=4). E. CFSE dilution showing proliferation of 
the indicated cell populations during IL-2 culture of TIL. Differences were assessed by Mann-Whitney U or one-way ANOVA.
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of an adaptive immune response – comprising T cells at 
various stages of differentiation – instead of an expansion 
of TRM. In line with this, short-term culture of tumor 
digests with IL-2 revealed a heterogeneous expression of 
CD28 on CD103+ and CD103- TIL.
Based on our data and several recent publications 
on T cell infiltration and migration in(to) ovarian tumors 
[7, 11, 28, 29], we therefore propose a mode of action 
for the generation of CD103+ T cells. CD8+ T cells 
from the peripheral blood extravasate across the tumor 
vasculature and likely arrive in the small fibronectin/
collagen-rich stromal areas that surround the cancer islets. 
This assumption is supported by the observation that the 
density of CD8+ TIL in stromal areas of most HGSC 
tumors is considerably higher than in the neighboring 
epithelial tissue, suggesting CD8+ T cell migration into 
cancer islets is a limiting factor (this paper and [28]). 
Herein, expression of e.g. FasL on the tumor vasculature 
is likely to play a role in limiting CD8+ T cell migration 
[24]. After extravasation, collagen density and fiber 
structure likely function as a barrier for effective CD8+ 
TIL migration from stromal areas into the epithelium of 
ovarian tumors [28]. In HGSC tumors where the collagen 
adopts a non-ring-like open structure, CD8+ TIL can 
cross the stromal barrier and engage epithelial HGSC 
cells [28]. At this point, cancer cell-reactive CD8+ T 
cells likely engage peptide-MHC class I molecules on the 
epithelial cancer cell and T cell receptor (TCR) signaling 
is triggered. Concurrently, epithelial cell-secreted TGF-β 
triggers TGF-β receptor signaling in the CD8+ T cell, 
resulting in upregulation of CD103. In line with this, we 
observed several CD103+ TIL in confocal analyses on the 
border of stromal and epithelial areas. These TIL showed 
signs of migration into the epithelium as evidenced by 
the characteristic elongation of activated T cells. If the T 
cell:cancer cell interaction results in release of e.g. IFN-y, 
known immunosuppressive factors like PD-L1 are likely 
to be (transiently) upregulated, effectively shutting down 
the T cell. Reversing this immunosuppression by means 
of checkpoint inhibition and/or T cell agonistic antibodies 
is likely to reactivate the infiltrating CD103+ TIL and 
mediate cancer cell eradication.
Our data highlight three interesting immune-
modulating targets to achieve this, namely PD-1, CD137 
and CD27. Predominant co-expression of PD-1 on the 
CD103+ TIL in HGSC has previously been reported 
and may be a consequence of TCR signaling occurring 
more frequently/exclusively in CD103+ TIL compared 
to CD103- TIL [29]. In line with this supposition, we 
further report that the marker for recent T cell activation 
CD137 was also expressed in a higher fraction of CD103+ 
TIL than in CD103- TIL. Interestingly, both PD-1 and 
CD137 have been reported to define the tumor-reactive 
T cell repertoire and our data show both markers are 
largely expressed within the CD103+, but not CD103- 
TIL populations [23, 30]. In depth analysis of the TCR 
repertoire of both subpopulations therefore appears 
warranted. Further, combinatorial immunotherapeutic 
strategies that target PD-1, CD137 and/or CD27 are likely 
to provide meaningful clinical benefit to HGSC patients 
with a high number of CD103+ TIL. Several trials in this 
respect are ongoing and it will be interesting to see if 
CD103 can herein be employed as a treatment-response 
biomarker.
Another interesting aspect of our analysis of 
CD103+ TIL concerns their minimal capacity for 
expansion under standard IL-2 culture conditions. Several 
trials on adoptive T cell transfer in ovarian cancer have 
been conducted with minimal observed clinical benefit 
[31, 32]. Our data provide a possible explanation by 
showing that the infusion product obtained after expansion 
is likely reduced in the intraepithelial (tumor-reactive) 
CD103+ TIL population and predominantly comprised 
of CD4+ and stromal CD8+ T cells. Of note, such a 
differential expansion of TIL subsets has previously been 
reported in the context of rapid TIL expansion for clinical 
infusion using artificial antigen presenting K562 cells 
(K562 aAPC) [33]. aAPC that did not produce cytokines, 
or were transduced to secrete IL-2, preferentially 
expanded CD4+ cells, most of which were FoxP3+ Treg 
cells. By contrast, aAPC that secreted IL-21 promoted 
a significantly more expansion of CD8+ cells, while 
minimizing Treg expansion. Analogously, it is conceivable 
that the exposure to TGF-β primes CD8+ CD103+ TIL 
for differential responses to cytokines when compared 
to CD8+ CD103- TIL. Novel expansion protocols that 
incorporate alternative cytokines to IL-2 may therefore 
provide a way of expanding CD103+ TIL for therapy.
A caveat of our study is the lack of functional data 
on the anti-tumor effects of CD103+ and CD103- T cell 
populations in an autologous patient-derived xenograft 
(PDX) model. While we established PDX from several 
of the patients included in this study [34], we were 
unable to expand the low numbers of CD3+CD56-
TCRαβ+CD8αβ+CD4-CD103+ cells obtained after 
isolation by fluorescence-activated cell sorting. Indeed, 
culture of isolated TIL in the presence of IL-2 resulted 
in expansion of sorted CD3+ CD56- TCRαβ+ CD4+ and 
CD3+ CD56- TCRαβ+ CD8αβ+ CD4- CD103- cells, but 
not CD3+ CD56- TCRαβ+ CD8αβ+ CD4- CD103+ cells 
in 10/10 samples (data not shown). These data are in line 
with our results on the loss of CD103+ TIL from IL-2 
cultures as depicted in Figure 5.
Finally, we observed clear differences in the 
prognostic benefit of stromal and epithelial CD8+ 
and CD103+ cells in relation to the treatment regime 
(Supplementary Figure S1). Stromal CD8+ T cells were of 
no prognostic benefit in any of the patient groups analyzed, 
nor were total CD8+ cells. By contrast, epithelial CD8+ 
cells and total CD103+ cells were of prognostic benefit 
only in patients treated by primary surgery and adjuvant 
chemotherapy. Patients treated in the neo-adjuvant setting 
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did not benefit from CD8+ or CD103+ cell infiltration. 
Why patients treated in the neo-adjuvant setting do not 
benefit from T cell infiltration remains unclear, but may 
be related to underlying differences in the biology of these 
cancers [35] or to changes in the tumor microenvironment 
induced by chemotherapy [36]. 
In conclusion, our data indicate CD103+ TIL in 
HGSC are formed as the result of an adaptive anti-tumor 
immune response against HGSC. Combined checkpoint 
modulation that targets PD-1, CD137 and/or CD27 should 
be explored for treatment of HGSC patients with high 
numbers of CD103+ TIL.
MATERIALS AND METHODS
Patients and ethics
The patient cohort used for retrospective analysis 
of CD3, CD8 and CD103 infiltration has been reported 
previously [12]. In brief, patients with advanced stage 
(FIGO stage IIb) high-grade serous ovarian cancer were 
selected for analysis (N=186). 84 patients received primary 
surgery (PS) and 102 patients received neoadjuvant 
chemotherapy (NACT). All patient data was placed in 
an anonymous database, in which patient identity was 
protected by unique patient codes. According to Dutch 
law, no approval from our institutional review board was 
needed. Primary patient TIL used for prospective analysis 
of CD103+ TIL phenotype were isolated from fresh tumor 
samples obtained during cytoreductive surgery. Formalin-
fixed paraffin-embedded (FFPE) tissue was available from 
several patients for matched analysis. This material was 
obtained from surgical tumor waste for which patients 
gave informed consent. No additional approval from our 
institutional review board was needed under Dutch law.
Immunohistochemistry
Preparation of sections, antigen retrieval and 
blocking was performed as described previously [12]. 
Sections were incubated with either rabbit-anti human 
CD103 mAb (anti-αEβ7-integrin, Abcam, Cambridge, 
UK, 1:200 in blocking buffer), mouse-anti human CD8 
mAb (DAKO, Heverlee, Belgium, clone C8/144B, 1:25 
in blocking buffer), mouse-anti human CD3 mAb (DAKO 
1:25 in blocking buffer) or rabbit anti-human pSMAD2/3 
(D27F4, Cell signaling, 1:50 in blocking buffer) overnight 
at 4°C. Slides were subsequently incubated with a 
peroxidase-labeled polymer (Envision+ anti-rabbit or anti-
mouse; DAKO). For CD103, a Biotin Tyramide working 
solution was used according to the manufacturer’s 
instructions (TSA Kit Perkin Elmer, Waltham, USA 1:50) 
and slides were incubated with streptavidin-HRP (TSA 
kit, Perkin Elmer, Waltham, USA 1:100). Specific signal 
for all staining was visualized by 3,3’diaminobenzidin 
(DAB). Slides were counterstained with hematoxylin. 
For each core the percentage of tumor/stromal surface 
was estimated based on consecutive H&E slides using 
semi-quantitative estimation. The total number of 
cells that stained positive for CD103 was counted per 
core and corrected for the total surface area of the core 
(epithelium+stroma). For CD3+ and CD8+ cells, the intra-
epithelial and stromal cells were counted separately and 
corrected for the surface area of each individual area. For 
epithelial counts patients were included if at least two 
cores contained >20% tumor epithelium. For stromal 
counts, patients were included if at least two of the cores 
contained >10% stroma and >20% tumor epithelium. 
For pSMAD2/3 staining, epithelial and stromal regions 
of individual cores were scored for no (0), low (1), 
intermediate (2) or high (3) expression and the sum of 
all 3 cores per patient used as the final score. For whole 
tumor sections, three individual 1 mm2 regions of tumor 
epithelium were selected and counted. All slides were 
counted manually by two individuals that were blinded 
for clinicopathological data. The two individual scores 
were compared, and differences in counts of over 10% 
were reanalyzed until consensus was reached. Epithelial 
CD27+ cell counts were reported previously [12]. 
Immunofluorescence
Preparation of sections, antigen retrieval and 
blocking was performed as described previously [12]. 
Sections were incubated overnight with rabbit-anti human 
CD103 mAb, washed and incubated with Envision-HRP 
anti-rabbit followed by fluorophore tyramide amplification 
diluents (TSA KIT Perkin Elmer, MA, USA 1:50) 
according to the manufacturer’s instructions. Next, slides 
were incubated overnight at 4°C with mouse anti-human 
CD8 (DAKO, Heverlee, Belgium, clone C8/144B, 1:25 
in blocking buffer) and rabbit anti-human pSMAD2/3 
(D27F4, Cell signaling, 1:50 in blocking buffer). Sections 
were subsequently incubated with goat-anti-mouse Alexa 
Fluor 555 (Life Technologies, Eugene, OR, USA GαM-
AF555, 1:150) and goat-anti-rabbit Alexa Fluor 488 (Life 
Technologies, Eugene, OR, USA 1:150). Nuclei were 
visualized with DAPI. Sections were embedded in prolong 
Gold anti-fade mounting medium (Life Technologies, 
Eugene, OR, USA) and scanned using a TissueFaxs 
imaging system (TissueGnostics, Vienna, Austria). 
Processed channels were merged using Adobe Photoshop. 
Analysis was performed using Fiji [37]. 
Tumor digests and TIL cultures
Fresh tumor material was obtained from patients 
undergoing cytoreductive surgery (n=20). With a scalpel, 
tumor pieces of approximately 1 mm3 were cut, and 
subjected to enzymatic digestion (RPMI supplemented 
with 1 mg/ml collagenase type IV (Life technologies) and 
31 U/ml rhDNase (Pulmozyme, Genentech, California, 
USA)) for 30 minutes at 37°C or overnight at room 
temperature. Subsequently, the digestion medium 
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containing remaining tumor pieces was filtered over a 70 
μm cell strainer (Corning, Amsterdam, The Netherlands). 
For phenotypic analyses, cells were pelleted, washed, 
and cryopreserved until further use. For TIL culture, 
cells were pelleted, washed and cultured in AIM-V 
medium containing 5% pooled human AB serum (Life 
Technologies) and 6000 IU/ml IL-2 (PROLEUKIN, 
Novartis). TIL cultures were routinely phenotyped 
using the antibodies described below. For proliferation 
assays, TIL cultures were labeled using the CellTrace™ 
CFSE Cell Proliferation Kit for flow cytometry 
(Life Technologies) according to the manufacturer’s 
instructions.
Flow cytometric analysis
CD103+ TIL phenotype was characterized by 
multiparameter flow cytometry in combination with 
fluorescence-activated cell sorting (FACS). The Zombie 
Aqua Fixable Viability Kit (BioLegend, Uithoorn, The 
Netherlands) was used for live/dead staining according 
to the manufacturer’s instructions. Antibodies used for 
analysis and cell sorting of CD103+ cells in HGSC tumor 
digests were CD3-BV421 (OKT3), CD103-FITC (ber-
ACT8), CD56-PE (clone CMSSB) (all BD Biosciences, 
Ettenleur, The Netherlands), CD4-PerCP-CY5.5 (OKT4), 
CD8β-PE-Cy7 (clone SIDI8BEE), TCRαβ-APC (IP26) 
and CD8α-APC-eFluor780 (RPA-T8) (all eBioscience, 
Vienna, Austria). Flow cytometry and cell sorting was 
performed on a Beckman Coulter MoFlo Astrios (BD 
Biosciences). For analysis of T cell differentiation 
in HGSC digests a combination of CCR7-BV421 
(clone 150503), CD103-FITC (ber-ACT8) (both BD 
Biosciences), CD27-APC (M-T271), CD45RO-PE-
Cy7 (UCHL1), CD28-PerCP-Cy5.5 (CD28.2), CD3-
PE (OKT3), CD8α-APC-eFluor780 (RPA-T8) (all 
eBioscience) and CD27-FITC (PeliCluster F) (Sanquin 
PeliCluster, Amsterdam, The Netherlands) were used. 
For analysis of expression of checkpoint molecules and 
costimulatory TNF family members in HGSC digests 
the following antibodies were used: CD134(OX40)-PE-
Cy7 (ACT35), CD270(HVEM)-Alexa Fluor 647 (clone 
94801), CD278(ICOS)-BV421 (DX29), CD272(BTLA)-
APC (J168-540), CD30-PE (clone 550041) (all from 
BD Biosciences), CD357(GITR)-PE-Cy7 (eBioAITR), 
CD137-PE (4B4), PD1-APC (MIH4), CD95-PE-
Cy7 (DX2), CD28-PerCP-Cy5.5 (CD28.2) (all from 
eBioscience) and CD27-FITC (PeliCluster F) (Sanquin 
PeliCluster). For analysis of T cell activation, HLA-
DR-BV421 (G46-6) CD103-FITC (ber-ACT8) (both 
BD Biosciences), CD137-PE (4B4), CD3-PerCP-CY5.5 
(OKT3), CD134(OX40)-PE-Cy7 (ACT35) and CD8α-
APC-eFluor780 (RPA-T8) were used (all eBioscience). 
Flow cytometry was performed on a BD FACSVerse and 
samples were analyzed with Cytobank software (cytobank.
org). For phenotyping of TIL cultures, the aforementioned 
antibodies were used in various combinations as indicated 
in the manuscript, acquired on a BD Accuri C6 flow 
cytometer (BD Biosciences) and analyzed using the 
accompanying software.
Coculture assays for induction of CD103
Freshly isolated PBMCs were activated with 
purified anti-CD3 monoclonal antibody OKT3 (1:1000, 
eBioscience) in the presence or absence of HGSC-cell lines 
PEA-1, PEA-2, PEO-14, PEO-23, OVCAR-3 (all routinely 
profiled using STR and mycoplasm screening assays). Cell 
lines were cultured using RPMI supplemented with 10% 
FCS, 1% Glutamine and 1% Sodium pyruvate for PEA-
1, PEA-2, PEO-14 and PEO-23, and RPMI supplemented 
with 10% FCS for OVCAR-3. All co-culture experiments 
were performed in AIM-V medium supplemented with 
5% pooled human AB serum. Where indicated, cells were 
additionally incubated with 40 μM TGFβR1 inhibitor SB-
431542 (Sigma-Aldrich, Zwijndrecht, The Netherlands) 
or recombinant TGFβ (Peprotech, Rocky Hill, United 
States). For proliferation assays, PBMC were labeled 
using the CellTrace™ CFSE Cell Proliferation Kit for 
flow cytometry (Life Technologies) according to the 
manufacturer’s instructions. For analysis of antigen-
specific immunity, OVCAR-3 cells were transfected 
with CMV pp65 protein using the pCMV6-pp65 Origene 
expression vector (VC101404-OR; Origene). Cells were 
cultured under G418 selection and used when >90% cells 
were pp65+ as assessed by antibody-based staining (IQ 
products clones C10/C11). PBMCs isolated from a CMV-
seropositive donor (assessed by IgG antibodies to CMV) 
were co-cultured with pp65+ OVCAR-3 or wildtype 
OVCAR-3 cells for the indicated periods and effector-to-
target (E:T) ratios and apoptosis assessed using Annexin-V 
staining (Immunotools). CD103+ cells induced after 
5 days of co-culture were sorted using CD103-FITC (ber-
ACT8) antibody and magnetic anti-mouse beads (Miltenyi 
Biotech) according to the manufacturer’s instructions. 
Where indicated, cells were phenotyped using the antibody 
panel described above.
Statistics
All statistical analyses were performed using IBM 
SPSS version 22 (SPSS Inc., Chicago, USA) or Graphpad 
Prism. Survival analysis was performed using the Kaplan-
Meier method with Log Rank test to test for differences 
between groups. Groups were stratified on the basis of the 
highest tertile. Differences in cell infiltration between 43 
matched ovarian and omental primary tumor tissues were 
assessed by Wilcoxon signed ranks test, no differences 
were found and therefore primary ovarian and omental 
tissues were used in the analyses. To determine differences 
in cell populations between clinicopathological variables 
or between different TIL subsets, the Mann-Whitney U 
or one-way ANOVA test were used. Spearman's rank 
correlation coefficient was used to determine correlation 
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between epithelial and stromal CD3+ and CD8+ TIL and 
total CD103+ TIL. All tests were performed two-sided, 
and p-values <0.05 were considered significant.
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